- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Nintedanib benefits patients with autoimmune disease-related lung diseases

A new clinical published in Arthritis & Rheumatology reveals that nintedanib, a medication that helps prevent changes to lung tissue, may help patients with fibrosing autoimmune disease-related interstitial lung diseases (ILDs), which are a common manifestation of systemic autoimmune diseases such as rheumatoid arthritis.In the trial, 170 patients with autoimmune disease-related ILDs...
A new clinical published in Arthritis & Rheumatology reveals that nintedanib, a medication that helps prevent changes to lung tissue, may help patients with fibrosing autoimmune disease-related interstitial lung diseases (ILDs), which are a common manifestation of systemic autoimmune diseases such as rheumatoid arthritis.
In the trial, 170 patients with autoimmune disease-related ILDs were randomized to nintedanib or placebo. Investigators assessed patients' forced vital capacity (FVC), or the maximum amount of air one can forcibly exhale from the lungs after fully inhaling. (FVC is a predictor of mortality in patients with autoimmune disease-associated ILDs.)
The rate of decline in FVC over one year was -75.9 mL/year with nintedanib versus -178.6 mL/year with placebo.
"Until now, therapies that can significantly reduce the rate of decline in lung function in connective tissue disease–related ILDs characterized by progressive fibrosis have been lacking. We now have a therapeutic approach that offers a strategy for reducing the morbidity associated with these diseases," said lead author Eric L. Matteson, MD, MPH, of the Mayo Clinic College of Medicine and Science.
https://onlinelibrary.wiley.com/doi/10.1002/art.42075
Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email:Â editorial@medicaldialogues.in. Contact no. 011-43720751